Zealand Pharma A/S. Overview
Latest P/E ratio for Zealand Pharma A/S.: 7.14 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow7.14
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ZEAL is 7.14. That is below the Healthcare sector average of 24.78. Investors often review this figure alongside Zealand Pharma A/S.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ZEAL currently prints 7.14 for P/E ratio, while the sector average sits near 24.78. That is roughly 71.2% below the sector mean. Large gaps often invite a closer look at Zealand Pharma A/S.'s growth, margins, and balance sheet.
A P/E ratio of 7.14 for Zealand Pharma A/S. is not 'good' or 'bad' on its own. Compare it with the peer average (24.78) and with ZEAL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ZEAL's P/E ratio (7.14), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Zealand Pharma A/S.'s P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
